ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 2,850 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $84.12, for a total transaction of $239,742.00. Following the completion of the sale, the chief financial officer directly owned 177,543 shares of the company’s stock, valued at $14,934,917.16. The trade was a 1.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Performance

Shares of ANIP traded down $1.33 during mid-day trading on Tuesday, hitting $82.78. 238,730 shares of the company’s stock were exchanged, compared to its average volume of 391,150. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a fifty-two week low of $62.60 and a fifty-two week high of $99.50. The business’s 50 day moving average is $80.70 and its two-hundred day moving average is $79.34. The firm has a market capitalization of $1.88 billion, a P/E ratio of 20.96 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on ANIP. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings raised shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, June 23rd. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $107.33.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. KBC Group NV acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at approximately $28,000. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Hantz Financial Services Inc. grew its holdings in ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after acquiring an additional 249 shares during the period. Kemnay Advisory Services Inc. acquired a new position in ANI Pharmaceuticals during the fourth quarter worth $48,000. Finally, State of Wyoming purchased a new position in ANI Pharmaceuticals in the second quarter worth $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.